Skip to main content

Table 2 Independent favorable prognostic factor for intracranial PFS* and OS

From: Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity

Outcome

Variable

Hazard ratio

95% CI

P

Intracranial PFS

SRS and nivolumab

0.54

0.32–0.92

0.038

fmulti-fraction SRS

0.48

0.28–0.87

0.015

OS

SRS and nivolumab

0.51

0.28–0.81

0.019

multi-fraction SRS

0.54

0.33–0.96

0.043

KPS >70

0.34

0.23–0.78

0.010

absent extracranial disease

0.50

0.29–0.81

0.018

  1. Abbreviations: OS, overall survival; PFS, progression-free survival;HR, hazard ratio; CI, confidence interval; *Variables with a significance of p < 0.05 at univariate analysis were included in the multivariate analysis. The following variables were evaluated: age, gender, Karnofsly Perforance Status (KPS) score, histology, extracranial disease status, systemic therapy, number of metastases, time to brain metasases development, conformity index, and irradiated volumes